Clinical trials: Treatment Failure
Heart Failure
Attain Performa(TM) Quadripolar Lead Study
The purpose of the study is to evaluate the safety and efficacy of the Medtronic Attain Performa Quadripolar Leads (Model 4298, 4398, and 4598) during and post the implant procedure.
- Trial name
- NCT01751022
- Testing
- Device: Attain Performa Pacing Lead (along with a standard CRT-D system)
- Where
- 121 sites in United States, Australia and 25 more
- Volunteers
- 1,202 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Severe Aplastic Anemia (SAA)
Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia
This study was designed to evaluate the efficacy and safety of eltrombopag when added to r-ATG and CsA in treatment naive East-Asian adult and pediatric patients with severe aplastic anemia (SAA).
- Trial name
- REACTS (NCT04328727)
- Testing
- eltrombopag, rabbit anti-thymocyte globulin (r-ATG), cyclosporine A (CsA)
- Where
- 12 sites in China, Japan and 2 more
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients
This is a phase IV, prospective, randomized, double-blind, double-dummy, parallel-group study. The study assessed the effects of 6 weeks of stable sacubitril/valsartan therapy, as compared with valsartan therapy, on the…
- Trial name
- TurkuPET (NCT03300427)
- Testing
- sacubitril/valsatran, valsartan
- Where
- Finland
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Critically Ill Renal Failure Requiring CVVHD and Oseltamivir, Critically Ill Requiring ECMO and Oseltamivir
Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)
Critically ill patients with flu may receive a drug called oseltamivir. They may also receive medical therapies to support their lung function (extracorporeal membrane oxygenation; ECMO) and kidney function (continuous venovenous…
- Trial name
- NCT01048879
- Testing
- pharmacokinetic blood sampling, pharmacokinetic blood and dialysate sampling
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Michigan
HIV-1-infection
Population Effectiveness of Dolutegravir Implementation in Sub-Saharan Africa
This is a prospective observational cohort study enrolling participants in South Africa and Uganda who are prescribed an HIV treatment regimen containing lamivudine, tenofovir, and dolutegravir, which is known as TLD.
- Trial name
- DISCO (NCT04066036)
- Testing
- This is an observational study only.
- Where
- 2 sites in South Africa, Uganda
- Volunteers
- 999 people
- Sponsor
- Massachusetts General Hospital
Dilated Cardiomyopathy
Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy
Several studies have documented that transplantation of bone marrow-derived cells (BMC) following acute myocardial infarction is associated with a reduction in infarct scar size and improvements in left ventricular function and…
- Trial name
- NCT00629018
- Testing
- CD34+ autologous stem cell transplantation, Bone Marrow Stimulation, SC therapy
- Where
- Slovenia
- Volunteers
- 110 people
- Sponsor
- University Medical Centre Ljubljana
Hepatitis C Virus Infection
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
The purpose of this study was to evaluate the efficacy and safety of co-administration of glecaprevir (ABT-493)/pibrentasvir (ABT 530) plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 …
- Trial name
- MAGELLAN-3 (NCT02939989)
- Testing
- Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 33 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Study to Assess the Management of Synthetic Disease-modifying Antirheumatic Drug (DMARD) at the Onset of Adverse Events, Intolerance or Lack of Efficacy in Rheumatoid Arthritis (RA)
The purpose of this study is to find patterns in the use of non-biological DMARDs as the initial treatment of RA and how adverse events (AEs), intolerance or lack of efficacy may impact therapeutic decisions in real life in the…
- Trial name
- SAR-FAME (NCT02094326)
- Where
- 11 sites in Spain
- Volunteers
- 301 people
- Sponsor
- Fundación Andaluza de Reumatología
Symptomatic Paroxysmal Atrial Fibrillation (PAF)
FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation
Comparing efficacy and safety of isolation of the pulmonary veins (PV) using a Cryoballoon catheter versus a radiofrequency ablation with a ThermoCool catheter in patients with paroxysmal atrial fibrillation.
- Trial name
- NCT01490814
- Testing
- Electrical isolation of the pulmonary veins, Electrical isolation of pulmonary veins
- Where
- 19 sites in Czechia, France and 6 more
- Volunteers
- 769 people
- Sponsor
- Medtronic Cardiac Ablation Solutions
Heart Failure
HCV Positive Heart Donors
Study subjects active on the waiting list for a heart transplant at the NYU Langone Transplant Institute who are hepatitis C (HCV) negative will receive a heart transplant from a donor who tests positive for HCV.
- Trial name
- NCT03382847
- Testing
- Transplant with HCV positive donor, followed by surveillance and treatment of viremia
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- NYU Langone Health
Transplant; Failure, Kidney, EBV
Belatacept 3 Month Post Transplant Conversion Study
This study is being done to investigate the impact of changing immunosuppressive medications from tacrolimus (Prograf®) to belatacept (Nulojix®) between three (3) and six (6) months after kidney transplantation.
- Trial name
- NCT02213068
- Testing
- belatacept, Tacrolimus, MPA
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Lorenzo Gallon
Acute Kidney Injury, End-stage Renal Disease
Hemodynamic Effects of Blood Flow Variation in Continuous Renal Replacement Therapy
Purpose of this study is to evaluate the short-term hemodynamic effects of changes in blood flow rates in critically ill patients receiving continuous renal replacement therapy.
- Trial name
- NCT03078504
- Testing
- continuous renal replacement therapy using System One (TM) setup (Nxstage)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- St. Louis University
Heart Failure, Heart-assist Devices
PCORI-1310-06998 Trial of a Decision Support Intervention for Patients and Caregivers Offered Destination Therapy Heart Assist Device
The left ventricular assist device (LVAD) is growing rapidly among people dying from end-stage heart failure who are unable to get a heart transplant.
- Trial name
- DECIDE-LVAD (NCT02344576)
- Testing
- DT LVAD Decision Support Intervention
- Where
- 6 sites in United States
- Volunteers
- 445 people
- Sponsor
- University of Colorado, Denver
Diabetes Mellitus, Type 2
Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure
Primary objective: To demonstrate the superiority of insulin glargine over liraglutide in terms of percentage of patients reaching a Glycosylated Haemoglobin (HbA1c) < 7% at the end of the comparative period (24 weeks) in Type 2…
- Trial name
- EAGLE (NCT01117350)
- Testing
- Insulin glargine, Liraglutide, Metformin
- Where
- 136 sites in United States, Austria and 15 more
- Volunteers
- 978 people
- Sponsor
- Sanofi
Hepatic Encephalopathy
A Retrospective, Open-label, Uncontrolled Cohort Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West Haven Criteria) Hepatic Encephalopathy (HE) [The RETRO Study]
This is a retrospective study in adult patients with cirrhosis and grade 3 or 4 HE (West Haven Criteria) to evaluate the effectiveness and safety of lactulose retention enema in the treatment of deep grade HE (West Haven…
- Trial name
- NCT02377947
- Where
- 3 sites in India
- Volunteers
- 50 people
- Sponsor
- Abbott
Acute Heart Failure
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.
- Trial name
- RELAX-AHF-2 (NCT01870778)
- Testing
- RLX030
- Where
- 540 sites in United States, Argentina and 33 more
- Volunteers
- 6,600 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Congestive, Dilated Cardiomyopathy
Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure
The study is divided into 2 parts. In the first part, the safety of the gene transfer agent MYDICAR® will be evaluated. In the second part, the ability of MYDICAR® to improve heart function will be studied.
- Trial name
- CUPID (NCT00454818)
- Testing
- MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)
- Where
- 22 sites in United States
- Volunteers
- 51 people
- Sponsor
- Celladon Corporation
Heart Failure, Systolic, Diabetes Mellitus, Type 2
Treatment of Diabetes in Patients With Systolic Heart Failure
Investigator Initiated Study to study the effects of Canagliflozin 100 milligrams (mg) vs Sitagliptin 100 mg on parameters of aerobic exercise capacity (peak oxygen consumption [VO2]) and ventilator efficiency (minute ventilation…
- Trial name
- NCT02920918
- Testing
- Canagliflozin, Sitagliptin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Virginia Commonwealth University
Kidney Transplantation, Chronic Kidney Failure
Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients
The toxicity of calcineurin inhibitors(CNI)is a major factor limiting the success of renal transplantation. This protocol aims to replace the calcineurin inhibitor, tacrolimus, with efalizumab early after transplantation in…
- Trial name
- NCT00472082
- Testing
- efalizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Type 2 Diabetes Mellitus
Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes
Although the efficacy and safety profile of exenatide has been well established, few data exist on the real world results of exenatide treatment in specific populations and clinical settings.
- Trial name
- NCT01060059
- Testing
- exenatide, basal insulin
- Where
- 50 sites in Italy
- Volunteers
- 888 people
- Sponsor
- AstraZeneca